| HBS Case Collection
Novartis' Sandoz: Between Generics and Pharma
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?
Keywords: Global Strategy and Leadership;
Managing Within a Multi-Business Organization;